NASDAQ:ITMN - InterMune Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About InterMune (NASDAQ:ITMN)

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Receive ITMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ITMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ITMN
CUSIP45884X10
WebN/A
Phone+1-415-4662200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

InterMune (NASDAQ:ITMN) Frequently Asked Questions

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Who are some of InterMune's key competitors?

Has InterMune been receiving favorable news coverage?

Press coverage about ITMN stock has trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. InterMune earned a news sentiment score of 0.16 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of InterMune?

Shares of ITMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact InterMune?

InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.


MarketBeat Community Rating for InterMune (ITMN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe ITMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InterMune (NASDAQ:ITMN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/22/2016 forward)

Earnings

InterMune (NASDAQ:ITMN) Earnings History and Estimates Chart

Earnings by Quarter for InterMune (NASDAQ:ITMN)

InterMune (NASDAQ ITMN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details
2/24/2014Q4 2013($0.66)($0.67)$25.63 million$25.69 millionViewN/AView Earnings Details
10/30/2013Q3 2013($0.71)($0.62)$16.42 million$19.72 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details
7/23/2012$0.10$0.01ViewN/AView Earnings Details
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details
2/16/2011$0.64$3.34ViewN/AView Earnings Details
10/28/2010Q3 2010($0.50)($0.44)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.61)($0.46)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.58)($0.66)ViewN/AView Earnings Details
2/17/2010Q4 2009($0.70)($0.62)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.21)($0.14)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.58)($0.60)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.85)($0.68)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.72)($0.74)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.53)($0.32)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.59)($0.68)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.58)($0.68)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.73)($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

InterMune (NASDAQ:ITMN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

InterMune (NASDAQ ITMN) Insider Trading and Institutional Ownership History

Insider Trading History for InterMune (NASDAQ:ITMN)

InterMune (NASDAQ ITMN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.0065,056View SEC Filing  
5/8/2014Sean NolanVPSell2,644$35.85$94,787.4072,556View SEC Filing  
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.3298,106View SEC Filing  
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.9546,672View SEC Filing  
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.0026,416View SEC Filing  
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.0087,434View SEC Filing  
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00137,434View SEC Filing  
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.6430,500View SEC Filing  
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.0014,158View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

InterMune (NASDAQ ITMN) News Headlines

Source:
DateHeadline
Ex-InterMune executive, friend found liable for insider tradingEx-InterMune executive, friend found liable for insider trading
uk.finance.yahoo.com - November 14 at 5:56 PM
The Push and Pull of Gender for Muslims at the HajjThe Push and Pull of Gender for Muslims at the Hajj
www.nytimes.com - September 15 at 6:08 PM
Netflixs White Helmets Highlights a Syrian Rescue Group on the Front LineNetflix's 'White Helmets' Highlights a Syrian Rescue Group on the Front Line
www.nbcnews.com - September 15 at 6:08 PM
Indians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh FestivalIndians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh Festival
www.nytimes.com - September 15 at 6:08 PM
Roche to buy California biotech firm InterMune for $8.3 billionRoche to buy California biotech firm InterMune for $8.3 billion
www.latimes.com - August 24 at 7:29 PM

SEC Filings

InterMune (NASDAQ:ITMN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

InterMune (NASDAQ:ITMN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

InterMune (NASDAQ ITMN) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.